Barclays PLC Bluebird Bio, Inc. Put Options Transaction History

Barclays PLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2019 Feb 10, 2020	SELL	$46.96 - $61.67 $46,960 - $61,670	-1,000 Reduced 40.0%	1,500 $132,000
Q3 2019 Nov 14, 2019	BUY	$59.47 - $93.1 $59,470 - $93,100	1,000 Added 66.67%	2,500 $230,000
Q1 2019 May 15, 2019	SELL	$64.44 - $104.11 $57,996 - $93,699	-900 Reduced 37.5%	1,500 $236,000
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $1.08 Million - $1.43 Million	-12,200 Reduced 83.56%	2,400 $350,000
Q2 2018 Aug 14, 2018	SELL	$99.64 - $127.59 $6.6 Million - $8.45 Million	-66,200 Reduced 81.93%	14,600 $2.29 Million
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $8.38 Million - $12 Million	79,200 Added 4950.0%	80,800 $13.8 Million
Q4 2017 Feb 14, 2018	SELL	$81.25 - $130.7 $32,500 - $52,279	-400 Reduced 20.0%	1,600 $285,000
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $115,480 - $182,840	2,000	2,000 $275,000

150

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $677M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.